TS-005570 — A new way of using cardiac myosin activators can be used to treat underactive urinary bladder. Poor urinary bladder contraction, which affects millions of individuals, can be caused by many diseases and has no effective treatments. By repurposing existing cardiac myosin MYH7-activating drugs and designing new myosin-binding ligands, clinicians can improve detrusor smooth muscle (dSM) myosin MYH11 contraction. With this redesigned drug, clinicians can target smooth muscle myosin MYH11 to improve the contraction of visceral muscle.

TS-005568 — This new approach to using alpha-1 adrenoreceptor antagonists for fetal lower urinary tract obstruction (LUTO) therapeutically relaxes the obstructed fetal bladder outlet, thereby improving bladder emptying and preventing damage to fetal organs. LUTO impairs fetal bladder emptying, leading to megabladder, back‑pressure injury to the kidneys, and critically low amniotic fluid, which is essential for normal lung development. Currently, the only available treatments involve invasive surgeries that carry substantial risks and can fail or require repeat procedures. This is the first approach of its kind to describe the use of TAM or other α‑1 blockers as a targeted fetal therapy, making this method of use novel and potentially groundbreaking.